View all newsletters
Receive our newsletter – data, insights and analysis delivered to you

Novo Nordisk Submits MAA for Oral Semaglutide

Novo Nordisk has announced the submission of a marketing authorisation application (MAA) to the European Medicines Agency (EMA) for oral semaglutide, a glucagon-like peptide-1 (GLP-1) analogue tablet.

To be used as a treatment of adults with Type 2 diabetes, this once-daily oral formulation utilises Emisphere Technologies’ proprietary Eligen® SNAC Carrier Technology.

Oral semaglutide has now been submitted for regulatory approval in the US, the EU and Canada.

riginally published by Elsevier Journals on 24 May 2011, this white paper outlines an open-label, randomised, single-dose, parallel-group study of the pharmacokinetics of oral cyanocobalamin...
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena